GLPG (Galapagos N.V.) Net Profit

Corporate emblem and logo of glpg.com (GLPG)

European biotech Galapagos NV relies on the search for molecules to combat inflammation. This development is complemented by a transition toward local CAR-T therapy production within clinics. The company's aggregate net income on the chart confirms these trends, with the indicator holding at 0.40. Currently, the portfolio of fibrosis and arthritis treatments is undergoing a deep update to achieve maturity.

GLPG (Galapagos) Company Net Income history from 07/04/2022 to 05/08/2026

Financial and market metric breakdowns for Galapagos (GLPG)

- price and consensus price forecast:
Stock Quotes Galapagos Corp|GLPG - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Galapagos Corp|GLPG - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Galapagos|GLPG - Company Book Value|Market-to-Book Ratio glpg.com|GLPG - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Galapagos NV|GLPG - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Galapagos N.V.|GLPG - Company Aggregate Debts|Debts to Book Value Galapagos Corp|GLPG - Company Long-Term Debt|Company Short-Term Loans and Borrowings Galapagos|Critical Liquidity glpg.com
- net income and valuation multiples indicators:
GLPG - Net Profit
Fundamental valuation:GLPG Galapagos Corp
Flagship merchandise of Galapagos N.V.

This indicator reflects the actual operational outcome of activities, stripped of market noise, which allows for an assessment of the business's fundamental stability through net income dynamics. Analyzing the company's financial results helps determine the risk of overpayment, while for Galapagos NV (GLPG), the stability of this metric is ensured by royalties and strategic collaboration with global pharma behemoths.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|ANIP: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Net Profit AQST (Aquestive Therapeutics, Inc.)|Annual Net Income scPharmaceuticals, Inc.|Tectonic - Net Profit|TNXP - Net Profit|sxtchina.com (SXTC) - Company Net Income|EPRX (Eupraxia Pharmaceuticals Inc.) - Company Net Income|BHST (BioHarvest Sciences Inc.) - Net Profit|Net Profit Invizyne Technologies|Company Net Income Oramed Pharmaceuticals (ORMP)|ENTX: Profit After Tax|Net Profit HYFT (MindWalk Holdings)|Net Profit abvcpharma.com ABVC|Cumberland Pharmaceuticals Inc. - Net Profit|Annual Net Income Quantum BioPharma Ltd. (QNTM)|FibroGen Corp (FGEN) - Company Net Income|Company Net Income Telomir Pharmaceuticals Corp (TELO)|Company Net Income Rani Therapeutics Holdings|Synergy CHC Corporation (SNYR) - Net Financial Result|Net Income RLYB (Rallybio Corporation)|LEXX (lexariabioscience.com) - Final Profit|Company Net Income Pulmatrix Corp PULM|PTHL: Company Profit|APM: Net Income|LYRA: Company Net Income|IBO: Net Profit|Annual Net Income TNF Pharmaceuticals, Inc. TNFA|Company Net Income cbdMD Inc.|Company Net Income PRFX|Company Net Income Altamira Therapeutics (CYTO)|LIPO: Profit After Tax|Net Profit OPTN (OptiNose)|Annual Net Income Pieris Pharmaceuticals Inc|PROC - Company Net Income|Profit After Tax PTPI|QLI: Net Profit|acelyrin.com - Final Profit|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit